Ottobock

Philipp Schulte-Noelle becomes CFO of Ottobock

The high-profile manager Philipp Schulte-Noelle is joining the management team of the international medical technology manufacturer Ottobock.

Philipp Schulte-Noelle becomes CFO

Ottobock completes company Management

The high-profile manager Philipp Schulte-Noelle is joining the management team of the international medical technology manufacturer under CEO Dr Oliver Scheel starting on 15 August. He also completes the Management Board under majority shareholder Professor Hans Georg Näder. "I am pleased that we were able to recruit Philipp Schulte-Noelle as CFO for Ottobock. He is ideal for filling this position. As CFO he will contribute crucial impulses for the company's transformation on our ambitious development path, decisively driving the success of our business. He is a perfect fit for our team."

Dr Oliver Scheel assumed the position of CEO on 15 January 2018 and put together a new management team. Dr Andreas Goppelt as Chief Technology Officer is responsible for the company's Research & Development. With Arne Jörn, a new Chief Operating Officer commenced his work in March of 2018. Ralf Stuch as CSMO is responsible for Marketing and Sales. He will remain the interim CFO until Philipp Schulte-Noelle comes on board. "With the new CFO, we have put together a new management team within half a year, enabling us to work on our profitability and growth targets with a full line-up in the third quarter," says Scheel.

In view of a possible IPO, Schulte-Noelle, born in Cologne, will dedicate himself to speeding up reporting and complying with IFRS (the International Financial Reporting Standards) in the future, among other things. His field of responsibility includes risk management in addition to finance.

41-year-old Schulte-Noelle took over Corporate Business Development/M&A at Fresenius SE & Co. KGaA in 2013. Since 2015 he has been CFO and labour director of Fresenius Kabi AG, a leading international supplier of generic intravenous drugs, clinical nutrition, infusion therapies, medical equipment, and infusion technology products with annual sales of EUR 6.4 billion (2017).

Schulte-Noelle previously collected relevant experience at Permira Beteiligungsberatung GmbH in Frankfurt and as Financial Analyst at the investment bank Goldman Sachs International in London.

"I am very pleased to drive the development of Ottobock as part of the team under Dr Oliver Scheel and the shareholders," says Philipp Schulte-Noelle. "Getting a family company that has been helping people recover their mobility for nearly 100 years ready for an IPO is an exciting challenge."

Head of Investor Relations & Corporate Communications
Mark C. Schneider
Ottobock SE & Co. KGaA, Ebertstr. 15a, 10117 Berlin, Germany
Phone: +49 30 398 206 222
Mobile: +49 151 146 591 35
Email: MarkC.Schneider@ottobock.de 



Weitere Meldungen: Ottobock

Das könnte Sie auch interessieren: